Eltrombopag

Eltrombopag is a hydrazine in which each nitrogen atom is substituted, one by a 3′-carboxy-2-hydroxy[1,1′-biphenyl]-3-yl group and the other by a 1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene group. A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to thrombocytopenia (abnormally low platelet counts). Among its listed roles, it functions as a thrombopoietin receptor agonist and a xenobiotic. It belongs to the class of hydrazines, a member of pyrazoles and a member of benzoic acids. Its therapeutic use is listed as hematologic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Promacta and Revolade. Its PubChem CID is 135449332.

CAS No 496775-61-2
Molecular Formula C25H22N4O4
Molecular Weight 442.5 g/mol
Synonyms 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid

Frequently Asked Questions